ClinicalTrials.gg
Active, not recruitingNCT05533463Updated Sep 8, 2025

Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

A Phase 1 interventional study of HRS-4642 in Advanced KRAS G12D Mutant Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups

02

Conditions studied

  • Advanced KRAS G12D Mutant Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must voluntarily agree to participate in the trial and sign a written form.
  2. Male or female ≥ 18 years old.
  3. confirmed diagnosis of advanced solid tumor harbouring with KRAS G12D mutation
  4. performance status of 0-1.
  5. With a of ≥3 months.
  6. Have at least one .
  7. Adequate laboratory parameters during the screening period

Exclusion criteria

Exclusion Criteria:

  1. Previously received KRAS G12D inhibitors
  2. Priot radiotherapy within 28 days for non-thoracic radiation
  3. Prior anti-tumor chemotherapy (\< 6 weeks if chemotherapy including nitrosoureas or mitomycin) within 4 weeks before the study drug administration
  4. Any unresolved AEs > (CTCAE) Grade 1 or inclusion/exclusion criteria level (The investigators determined that safe and controllable toxicity was excluded, such as alopecia and ≤ grade 2 peripheral neuropathy ).
  5. Central nervous system (CNS)
  6. Major surgical therapy within 28 days prior to the date of signature of form, or expected major surgery during the study.
  7. Known history of to any components of HRS-4642.
  8. Other factors that may affect the study results or lead to forced termination of the study early as judged by investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    HRS-4642

    In Dose Escalation: HRS-4642 will be injected QW. Six dose levels are preset. In Dose Expansion: 1 to 2 dose cohorts will be selected for dose expansion stage. In Indication Expansion: Enrollment into the dose expansion cohorts may be from any eligible solid tumor type.

    Drug: HRS-4642

Interventions

  • HRS-4642 will be administrated per dose level in which the patients are assigned.

06

What researchers measure

Primary outcomes

  1. Safety endpoints: adverse events(AEs), serious adverse events(SAEs).

    Assess safety and tolerability of HRS-4642 by way of adverse events (CTCAE v5.0).

    Time frame: 24 months

  2. Dose Limited Toxicity(DLT)

    A DLT is defined as any event meeting the DLT criteria occurring within 21 days of first dose on Cycle 1 Day 1 (C1D1), excluding toxicities clearly related to disease progression or intercurrent illness

    Time frame: from day 1 to Day 21

  3. Maximum tolerated dose (MTD)

    Incidence and category of dose limiting toxicities (DLTs) during the first 21-day cycle of HRS-4642 treatment.

    Time frame: From Day 1 to Day 21

  4. RP2D

    RP2D will be determined on the basis of evaluation on safety, PK, efficacy data in dose escalation and dose expansion stages.

    Time frame: 24 months

Secondary outcomes

  1. Number of Participants With Abnormal Laboratory Values

    Time frame: 24months.

  2. Number of subjects with clinically significant changes in ECOG, vital signs and physical examination.

    Time frame: 24months.

  3. Number of subjects with changes on ECG.

    Time frame: 24months.

  4. Efficacy endpoints: Overall response rate (ORR).

    Evaluated by RECIST v1.1.

    Time frame: 24months.

  5. Efficacy endpoints: Duration of response (DoR).

    Evaluated by RECIST v1.1

    Time frame: 24 months.

  6. Efficacy endpoints: Disease control rate (DCR).

    Evaluated by RECIST v1.1.

    Time frame: 24months.

  7. Efficacy endpoints: Progression free survival (DoR).

    Evaluated by RECIST v1.1.

    Time frame: 24months.

  8. Efficacy endpoints: overall survival (OS).

    Evaluated by RECIST v1.1

    Time frame: 24minths

  9. Cmax.

    Maximal plasma concentration.

    Time frame: 24 months.

  10. Tmax.

    Time to Cmax.

    Time frame: 24 months

  11. AUC.

    Area under the plasma concentration-time curve.

    Time frame: 24 months.

  12. t1/2.

    Terminal-phase elimination half-life.

    Time frame: 24 months.

  13. Vz/F.

    Apparent volume of distribution during terminal phase after non-intravenous administration.

    Time frame: 24 months.

  14. CL/F.

    Apparent total clearance of the drug from plasma after oral administration.

    Time frame: 24 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Jun 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2022
First posted
Sep 9, 2022
StartActual
Sep 21, 2022
Primary completionActual
Jun 25, 2024
CompletionEst.
Dec 30, 2025
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05533463
Responsible party
Sponsor
First posted
Sep 9, 2022
Start date
Sep 21, 2022
Primary completion
Jun 25, 2024
Completion
Dec 30, 2025 (estimated)
Last update
Sep 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12D Inhibitor HRS-4642

Start the discussion